{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T02:46:45Z","timestamp":1795056405205,"version":"4.10.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current guidelines for mammography screening for breast cancer vary across agencies, especially for women aged 40\u201349. Using artificial Intelligence (AI) to read mammography images has been shown to predict breast cancer risk with higher accuracy than alternative approaches including polygenic risk scores (PRS), raising the question whether AI-based screening is more cost-effective than screening based on PRS or existing guidelines. This study provides the first evidence to shed light on this important question.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a model-based economic evaluation. We used a hybrid decision tree\/microsimulation model to compare the cost-effectiveness of eight strategies of mammography screening for women aged 40\u201349 (screening beyond age 50 follows existing guidelines). Six of these strategies were defined by combinations of risk prediction approaches (AI, PRS or family history) and screening frequency for low-risk women (no screening or biennial screening). The other two strategies involved annual screening for all women and no screening, respectively. Data used to populate the model were sourced from the published literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Risk prediction using AI followed by no screening for low-risk women is the most cost-effective strategy. It dominates (i.e., costs more and generates fewer quality adjusted life years (QALYs)) strategies for risk prediction using PRS followed by no screening or biennial screening for low-risk women, risk prediction using AI or family history followed by biennial screening for low-risk women, and annual screening for all women. It also extendedly dominates (i.e., achieves higher QALYs at a lower incremental cost per QALY) the strategy for risk prediction using family history followed by no screening for low-risk women. Meanwhile, it is cost-effective versus no screening, with an incremental cost-effectiveness ratio of $23,755 per QALY gained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risk prediction using AI followed by no breast cancer screening for low-risk women is the most cost-effective strategy. This finding can be explained by AI\u2019s ability to identify high-risk women more accurately\u00a0than PRS and family history (which reduces the possibility of delayed breast cancer diagnosis) and fewer false-positive diagnoses from not screening low-risk women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-022-09613-1","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T05:06:28Z","timestamp":1651813588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening"],"prefix":"10.1186","volume":"22","author":[{"given":"Shweta","family":"Mital","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai V.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"9613_CR1","volume-title":"The high cost of breast cancer \u201cfalse positives.\u201d","author":"CBS News","year":"2015","unstructured":"CBS News. The high cost of breast cancer \u201cfalse positives.\u201d 2015. https:\/\/www.cbsnews.com\/news\/the-cost-of-breast-cancer-false-positives\/. Accessed 5 Apr 2020."},{"key":"9613_CR2","volume-title":"Breast Cancer Screening Guidelines for Women","author":"Centers for Disease Control and Prevention","year":"2016","unstructured":"Centers for Disease Control and Prevention. Breast Cancer Screening Guidelines for Women 2016. https:\/\/www.cdc.gov\/cancer\/breast\/pdf\/BreastCancerScreeningGuidelines.pdf."},{"key":"9613_CR3","volume-title":"New breast cancer screening guidelines are outdated and dangerous, experts say","author":"Global News","year":"2019","unstructured":"Global News. New breast cancer screening guidelines are outdated and dangerous, experts say. 2019. https:\/\/globalnews.ca\/news\/4898068\/breast-cancer-screening-guidelines-backlash\/. Accessed 4 Apr 2020."},{"key":"9613_CR4","first-page":"16","volume":"26","author":"N Mittmann","year":"2015","unstructured":"Mittmann N, Stout NK, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, et al. Total cost-effectiveness of mammography screening strategies. Health Rep. 2015;26:16.","journal-title":"Health Rep"},{"key":"9613_CR5","doi-asserted-by":"publisher","first-page":"E77","DOI":"10.9778\/cmajo.20170106","volume":"6","author":"N Mittmann","year":"2018","unstructured":"Mittmann N, Stout NK, Tosteson AN, Trentham-Dietz A, Alagoz O, Yaffe MJ. Cost-effectiveness of mammography from a publicly funded health care system perspective. CMAJ Open. 2018;6:E77.","journal-title":"CMAJ Open"},{"key":"9613_CR6","doi-asserted-by":"publisher","first-page":"dju397","DOI":"10.1093\/jnci\/dju397","volume":"107","author":"CM Vachon","year":"2015","unstructured":"Vachon CM, Pankratz VS, Scott CG, Haeberle L, Ziv E, Jensen MR, et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst. 2015;107:dju397.","journal-title":"J Natl Cancer Inst"},{"key":"9613_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1148\/radiol.2019182716","volume":"292","author":"A Yala","year":"2019","unstructured":"Yala A, Lehman C, Schuster T, Portnoi T, Barzilay R. A deep learning mammography-based model for improved breast cancer risk prediction. Radiology. 2019;292:60\u20136.","journal-title":"Radiology"},{"key":"9613_CR8","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaoncol.2018.1901","volume":"4","author":"N Pashayan","year":"2018","unstructured":"Pashayan N, Morris S, Gilbert FJ, Pharoah PD. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. 2018;4:1504\u201310.","journal-title":"JAMA Oncol"},{"key":"9613_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/jamaoncol.2016.1025","volume":"2","author":"P Maas","year":"2016","unstructured":"Maas P, Barrdahl M, Joshi AD, Auer PL, Gaudet MM, Milne RL, et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States. JAMA Oncol. 2016;2:1295\u2013302.","journal-title":"JAMA Oncol"},{"key":"9613_CR10","volume-title":"Breast Cancer Facts & Figures 2019\u20132020","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Breast Cancer Facts & Figures 2019\u20132020. Atlanta: American Cancer Society, Inc.; 2019. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-and-figures\/breast-cancer-facts-and-figures-2019-2020.pdf"},{"key":"9613_CR11","unstructured":"United States Preventive Services Taskforce. Breast Cancer. Screening. 2016; https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/breast-cancer-screening. Accessed 5 Apr 2020."},{"key":"9613_CR12","doi-asserted-by":"publisher","first-page":"700","DOI":"10.7326\/M16-0476","volume":"165","author":"A Trentham-Dietz","year":"2016","unstructured":"Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, et al. Tailoring breast cancer screening intervals by breast density and risk for women aged 50 years or older: collaborative modeling of screening outcomes. Ann Intern Med. 2016;165:700\u201312.","journal-title":"Ann Intern Med"},{"key":"9613_CR13","unstructured":"United States Preventive Services Taskforce. Grade definitions. https:\/\/epss.ahrq.gov\/ePSS\/gradedef.jsp. Accessed 15 Oct 2020."},{"key":"9613_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/0003-4819-155-1-201107050-00003","volume":"155","author":"JT Schousboe","year":"2011","unstructured":"Schousboe JT, Kerlikowske K, Loh A, Cummings SR. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med. 2011;155:10\u201320.","journal-title":"Ann Intern Med"},{"key":"9613_CR15","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1158\/1055-9965.EPI-17-0531","volume":"26","author":"OO Shiyanbola","year":"2017","unstructured":"Shiyanbola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, et al. Emerging trends in family history of breast cancer and associated risk. Cancer Epidemiol Prev Biomarkers. 2017;26:1753\u201360.","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"key":"9613_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1158\/1055-9965.EPI-16-0801","volume":"26","author":"TP Ahern","year":"2017","unstructured":"Ahern TP, Sprague BL, Bissell MCS, Miglioretti DL, Buist DSM, Braithwaite D, et al. Family history of breast Cancer, breast density, and breast Cancer risk in a U.S. breast Cancer screening population. Cancer Epidemiol Biomark Prev. 2017;26:938\u201344.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"9613_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jcpo.2015.03.002","volume":"5","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Miller AB. Why have breast cancer mortality rates declined? J Cancer Policy. 2015;5:8\u201317.","journal-title":"J Cancer Policy"},{"key":"9613_CR18","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaoncol.2015.3084","volume":"1","author":"DL Miglioretti","year":"2015","unstructured":"Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, Buist DS, et al. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. JAMA Oncol. 2015;1:1069\u201377.","journal-title":"JAMA Oncol"},{"key":"9613_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jval.2018.07.880","volume":"22","author":"Y-CT Shih","year":"2019","unstructured":"Shih Y-CT, Dong W, Xu Y, Shen Y. Assessing the cost-effectiveness of updated breast cancer screening guidelines for average-risk women. Value Health. 2019;22:185\u201393.","journal-title":"Value Health"},{"key":"9613_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-155-8-201110180-00005","volume":"155","author":"K Kerlikowske","year":"2011","unstructured":"Kerlikowske K, Hubbard RA, Miglioretti DL, Geller BM, Yankaskas BC, Lehman CD, et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med. 2011;155:493\u2013502.","journal-title":"Ann Intern Med"},{"key":"9613_CR21","volume-title":"The cost of AI in radiology: is it really worth it?","author":"European Society of Radiology","year":"2019","unstructured":"European Society of Radiology. The cost of AI in radiology: is it really worth it? 2019. https:\/\/ai.myesr.org\/healthcare\/the-cost-of-ai-in-radiology-is-it-really-worth-it\/. Accessed 4 Apr 2020."},{"key":"9613_CR22","volume-title":"Microarrays and Fees","author":"Iowa Institute of Human Genetics","year":"2020","unstructured":"Iowa Institute of Human Genetics. Microarrays and Fees 2020. https:\/\/medicine.uiowa.edu\/humangenetics\/research\/genomics-division\/microarray\/microarrays-and-fees. Accessed 4 Apr 2020."},{"key":"9613_CR23","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1001\/jamaoncol.2019.3323","volume":"5","author":"L Sun","year":"2019","unstructured":"Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol. 2019;5:1718\u201330.","journal-title":"JAMA Oncol"},{"key":"9613_CR24","volume-title":"Physician fee schedule search","author":"Centers for Medicare and Medicaid Services","year":"2020","unstructured":"Centers for Medicare and Medicaid Services. Physician fee schedule search. 2020. Https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/license-agreement.aspx. Accessed 4 apr 2020."},{"key":"9613_CR25","doi-asserted-by":"crossref","unstructured":"Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014;106:dju092.","DOI":"10.1093\/jnci\/dju092"},{"key":"9613_CR26","volume-title":"Euros (EUR) to US dollars (USD) Rates for 2\/26\/2020","author":"Exchange rates.org","year":"2020","unstructured":"Exchange rates.org. Euros (EUR) to US dollars (USD) Rates for 2\/26\/2020. 2020. https:\/\/www.exchange-rates.org\/Rate\/EUR\/USD\/2-26-2020."},{"key":"9613_CR27","volume-title":"MQSA National Statistics","author":"US Food and Drug Administration","year":"2020","unstructured":"US Food and Drug Administration. MQSA National Statistics. 2020. https:\/\/www.fda.gov\/radiation-emitting-products\/mqsa-insights\/mqsa-national-statistics. Accessed 4 Apr 2020."},{"key":"9613_CR28","unstructured":"US Census Bureau. 2018 Population estimates by age, sex, race and hispanic origin, vol. 2019. https:\/\/www.census.gov\/newsroom\/press-kits\/2019\/detailed-estimates.html. Accessed 4 Apr 2020"},{"key":"9613_CR29","doi-asserted-by":"crossref","unstructured":"Naber SK, Kundu S, Kuntz KM, Dotson WD, Williams MS, Zauber AG, et al. Cost-effectiveness of risk-stratified colorectal cancer screening based on polygenic risk: current status and future potential. JNCI Cancer Spectr. 2020;4(1):pkz086.","DOI":"10.1093\/jncics\/pkz086"},{"key":"9613_CR30","doi-asserted-by":"publisher","first-page":"e0152359","DOI":"10.1371\/journal.pone.0152359","volume":"11","author":"S Kundu","year":"2016","unstructured":"Kundu S, Kers JG, Janssens ACJ. Constructing hypothetical risk data from the area under the ROC curve: modelling distributions of polygenic risk. Plos One. 2016;11:e0152359.","journal-title":"Plos One"},{"key":"9613_CR31","volume-title":"Breast Cancer SEER incidence rates by age at diagnosis, 2013-2017","author":"National Cancer Institute Surveillance, Epidemiology, and End Results Program","year":"2020","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Breast Cancer SEER incidence rates by age at diagnosis, 2013-2017. 2020. https:\/\/seer.cancer.gov\/explorer\/application.html."},{"issue":"1_suppl","key":"9613_CR32","doi-asserted-by":"publisher","first-page":"32S","DOI":"10.1177\/0272989X17743236","volume":"38","author":"DF Munoz","year":"2018","unstructured":"Munoz DF, Plevritis SK. Estimating breast cancer survival by molecular subtype in the absence of screening and adjuvant treatment. Med Decis Mak. 2018;38(1_suppl):32S\u201343S.","journal-title":"Med Decis Mak"},{"key":"9613_CR33","unstructured":"Centers for Disease Control and Prevention. National Vital Statistics Report Volume 68, Number 7. United States Life Tables, 2017. https:\/\/www.cdc.gov\/nchs\/data\/nvsr\/nvsr68\/nvsr68_07-508.pdf. Accessed 21 Dec 2019."},{"key":"9613_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u2013103.","journal-title":"JAMA"},{"key":"9613_CR35","volume-title":"HERC: cost-effectiveness analysis.","author":"US Department of Veteran Affairs","year":"2020","unstructured":"US Department of Veteran Affairs. HERC: cost-effectiveness analysis. 2020. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=cost-effectiveness-analysis. Accessed 14 Oct 2020."},{"key":"9613_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104:21\u201334.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"9613_CR37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ijc.33593","volume":"149","author":"SA Khan","year":"2021","unstructured":"Khan SA, Hernandez-Villafuerte KV, Muchadeyi MT, Schlander M. Cost-effectiveness of risk-based breast cancer screening: a systematic review. Int J Cancer. 2021;149(4):790\u2013810.","journal-title":"Int J Cancer."},{"key":"9613_CR38","unstructured":"TreeAge Software. TreeAge Pro 2019, R2. https:\/\/www.treeage.com\/software-downloads\/treeage-pro-2019-r2\/. Accessed 17 Aug 2020."},{"key":"9613_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. PharmacoEconomics. 2016;34:349\u201361.","journal-title":"PharmacoEconomics"},{"key":"9613_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force\u20137. Med Decis Mak. 2012;32:733\u201343.","journal-title":"Med Decis Mak"},{"key":"9613_CR41","volume-title":"SEER*Explorer: An interactive website for SEER cancer statistics","author":"Surveillance Research Program, National Cancer Institute","year":"2020","unstructured":"Surveillance Research Program, National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics. 2020. https:\/\/seer.cancer.gov\/explorer\/index.html. Accessed 7 Oct 2020."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09613-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09613-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T05:06:58Z","timestamp":1651813618000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09613-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9613"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09613-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"501"}}